BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohanty A, Uthaman S, Park IK. Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy. Molecules 2020;25:E4377. [PMID: 32977707 DOI: 10.3390/molecules25194377] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Mohanty A, Park I. Protein-Caged Nanoparticles: A Promising Nanomedicine Against Cancer. Chonnam Med J 2023;59:1. [DOI: 10.4068/cmj.2023.59.1.1] [Reference Citation Analysis]
2 Hoffmann M, Gerlach S, Hoffmann C, Richter N, Hersch N, Csiszár A, Merkel R, Hoffmann B. PEGylation and folic-acid functionalization of cationic lipoplexes-Improved nucleic acid transfer into cancer cells. Front Bioeng Biotechnol 2022;10:1066887. [PMID: 36619382 DOI: 10.3389/fbioe.2022.1066887] [Reference Citation Analysis]
3 Ramzy A, ElSafy S, Elshoky HA, Soliman A, Youness R, Mansour S, Sebak A. Drugless nanoparticles tune-up an array of intertwined pathways contributing to immune checkpoint signaling and metabolic reprogramming in triple-negative breast cancer. Biomed Mater 2022;18. [PMID: 36541457 DOI: 10.1088/1748-605X/aca85d] [Reference Citation Analysis]
4 Dali P, Shende P. Self-Assembled Lipid Polymer Hybrid Nanoparticles Using Combinational Drugs for Migraine Via Intranasal Route. AAPS PharmSciTech 2022;24:20. [DOI: 10.1208/s12249-022-02479-3] [Reference Citation Analysis]
5 Zhou S, Zhao W, Hu J, Mao C, Zhou M. Application of Nanotechnology in Thrombus Therapy. Adv Healthc Mater 2022;:e2202578. [PMID: 36507827 DOI: 10.1002/adhm.202202578] [Reference Citation Analysis]
6 Madhi ZS, Shallan MA, Almaamuri AM, Alhussainy AA, Al- Salih SSS, Raheem AK, Alwan HJ, Jalil AT. Lipids and lipid derivatives for delivery of the CRISPR/Cas9 system. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.103948] [Reference Citation Analysis]
7 Ali AA, Al-Othman A, Al-Sayah M. Multifunctional stimuli-responsive hybrid nanogels for cancer therapy: Current status and challenges. J Control Release 2022:S0168-3659(22)00628-9. [PMID: 36170926 DOI: 10.1016/j.jconrel.2022.09.033] [Reference Citation Analysis]
8 Wang L, Pan T, Wang Y, Yu J, Qu P, Chen Y, Xin H, Wang S, Liu J, Wu Y. Effect of Nanoparticles of DOX and miR-125b on DNA Damage Repair in Glioma U251 Cells and Underlying Mechanisms. Molecules 2022;27:6201. [DOI: 10.3390/molecules27196201] [Reference Citation Analysis]
9 Choukaife H, Seyam S, Alallam B, Doolaanea AA, Alfatama M. Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment. Int J Nanomedicine 2022;17:3933-66. [PMID: 36105620 DOI: 10.2147/IJN.S375229] [Reference Citation Analysis]
10 Zeng Y, Shen Y, Wu S, Cai L, Wang Z, Cai K, Shen J, Hii Ru Yie K, Zhang H, Xu L, Liu J. Bone-targeting PLGA derived lipid drug delivery system ameliorates bone loss in osteoporotic ovariectomized rats. Materials & Design 2022;221:110967. [DOI: 10.1016/j.matdes.2022.110967] [Reference Citation Analysis]
11 Arruda DC, Lachagès AM, Demory H, Escriou G, Lai-Kuen R, Dugas PY, Hoffmann C, Bessoles S, Sarrabayrouse G, Malachias A, Finet S, Gastelois PL, de Almeida Macedo WA, da Silva Cunha A Jr, Bigey P, Escriou V. Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA. J Control Release 2022:S0168-3659(22)00535-1. [PMID: 35995297 DOI: 10.1016/j.jconrel.2022.08.030] [Reference Citation Analysis]
12 Xu L, Xie L, Fang C, Lou W, Jiang T. New progress in tumor treatment based on nanoparticles combined with irreversible electroporation. Nano Select 2022. [DOI: 10.1002/nano.202200064] [Reference Citation Analysis]
13 Wang S, Cheng K, Chen K, Xu C, Ma P, Dang G, Yang Y, Lei Q, Huang H, Yu Y, Fang Y, Tang Q, Jiang N, Miao H, Liu F, Zhao X, Li N. Nanoparticle-based medicines in clinical cancer therapy. Nano Today 2022;45:101512. [DOI: 10.1016/j.nantod.2022.101512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Setia A, Sahu RK, Ray S, Widyowati R, Ekasari W, Saraf S. Advances in Hybrid Vesicular-based Drug Delivery Systems: Improved Biocompatibility, Targeting, Therapeutic Efficacy and Pharmacokinetics of Anticancer Drugs. Curr Drug Metab 2022;23:757-80. [PMID: 35761494 DOI: 10.2174/1389200223666220627110049] [Reference Citation Analysis]
15 Khalili L, Dehghan G, Sheibani N, Khataee A. Smart active-targeting of lipid-polymer hybrid nanoparticles for therapeutic applications: Recent advances and challenges. Int J Biol Macromol 2022;213:166-94. [PMID: 35644315 DOI: 10.1016/j.ijbiomac.2022.05.156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang C, Yang J, Lu A, Gong J, Yang Y, Lin X, Li M, Xu H. Nanoparticles in ocular applications and their potential toxicity. Front Mol Biosci 2022;9:931759. [DOI: 10.3389/fmolb.2022.931759] [Reference Citation Analysis]
17 Ayad C, Yavuz A, Salvi JP, Libeau P, Exposito JY, Ginet V, Monge C, Verrier B, Arruda DC. Comparison of Physicochemical Properties of LipoParticles as mRNA Carrier Prepared by Automated Microfluidic System and Bulk Method. Pharmaceutics 2022;14:1297. [PMID: 35745869 DOI: 10.3390/pharmaceutics14061297] [Reference Citation Analysis]
18 Wang Y, Zhao C, Liu Y, Wang C, Jiang H, Hu Y, Wu J. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis. Mol Pharm 2022. [PMID: 35436123 DOI: 10.1021/acs.molpharmaceut.2c00073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Kazmi I, Al-abbasi FA, Imam SS, Afzal M, Nadeem MS, Altayb HN, Alshehri S. Formulation and Evaluation of Apigenin-Loaded Hybrid Nanoparticles. Pharmaceutics 2022;14:783. [DOI: 10.3390/pharmaceutics14040783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cao Y, Dong X, Chen X. Polymer-Modified Liposomes for Drug Delivery: From Fundamentals to Applications. Pharmaceutics 2022;14:778. [DOI: 10.3390/pharmaceutics14040778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
21 Roffo F, Ponsiglione AM, Netti PA, Torino E. coupled Hydrodynamic Flow Focusing (cHFF) to Engineer Lipid–Polymer Nanoparticles (LiPoNs) for Multimodal Imaging and Theranostic Applications. Biomedicines 2022;10:438. [DOI: 10.3390/biomedicines10020438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Gupta S, Tejavath KK. Nano Phytoceuticals: A Step Forward in Tracking Down Paths for Therapy Against Pancreatic Ductal Adenocarcinoma. J Clust Sci. [DOI: 10.1007/s10876-021-02213-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mohanty A, Uthaman S, Park I. Lipid–polymer hybrid nanoparticles as a smart drug delivery platform. Stimuli-Responsive Nanocarriers 2022. [DOI: 10.1016/b978-0-12-824456-2.00012-6] [Reference Citation Analysis]
24 Lokhande S, Shinde UA, Shrivastava A, Singh KH. Targeting of lipid/polymeric (hybrid) nanoparticles to brain tumors. Nanocarriers for Drug-Targeting Brain Tumors 2022. [DOI: 10.1016/b978-0-323-90773-6.00027-0] [Reference Citation Analysis]
25 Lotey NK, Pednekar S, Chaughule R. Hybrid Nanoparticles in Biomedical Applications. Nanomaterials for Cancer Detection Using Imaging Techniques and Their Clinical Applications 2022. [DOI: 10.1007/978-3-031-09636-5_13] [Reference Citation Analysis]
26 Mathew AP, Uthaman S, Bae EH, Lee JY, Park IK. Vimentin Targeted Nano-gene Carrier for Treatment of Renal Diseases. J Korean Med Sci 2021;36:e333. [PMID: 34931497 DOI: 10.3346/jkms.2021.36.e333] [Reference Citation Analysis]
27 Xu L, Wang X, Liu Y, Yang G, Falconer RJ, Zhao C. Lipid Nanoparticles for Drug Delivery. Advanced NanoBiomed Research 2022;2:2100109. [DOI: 10.1002/anbr.202100109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
28 Haque S, Cook K, Sahay G, Sun C. RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer. Pharmaceutics 2021;13:1694. [PMID: 34683988 DOI: 10.3390/pharmaceutics13101694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
29 C de S L Oliveira AL, Schomann T, de Geus-Oei LF, Kapiteijn E, Cruz LJ, de Araújo Junior RF. Nanocarriers as a Tool for the Treatment of Colorectal Cancer. Pharmaceutics 2021;13:1321. [PMID: 34452282 DOI: 10.3390/pharmaceutics13081321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Le QV, Lee J, Lee H, Shim G, Oh YK. Cell membrane-derived vesicles for delivery of therapeutic agents. Acta Pharm Sin B 2021;11:2096-113. [PMID: 34522579 DOI: 10.1016/j.apsb.2021.01.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
31 Wei W, Li R, Liu Q, Devanathadesikan Seshadri V, Veeraraghavan VP, Surapaneni KM, Rengarajan T. Amelioration of oxidative stress, inflammation and tumor promotion by Tin oxide-Sodium alginate-Polyethylene glycol-Allyl isothiocyanate nanocomposites on the 1,2-Dimethylhydrazine induced colon carcinogenesis in rats. Arabian Journal of Chemistry 2021;14:103238. [DOI: 10.1016/j.arabjc.2021.103238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Szumilak M, Wiktorowska-Owczarek A, Stanczak A. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance? Molecules 2021;26:2601. [PMID: 33946916 DOI: 10.3390/molecules26092601] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
33 Persano F, Gigli G, Leporatti S. Lipid-polymer hybrid nanoparticles in cancer therapy: current overview and future directions. Nano Ex 2021;2:012006. [DOI: 10.1088/2632-959x/abeb4b] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
34 Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021;14:215. [PMID: 33806527 DOI: 10.3390/ph14030215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Kim EM, Jeong HJ. Liposomes: Biomedical Applications. Chonnam Med J 2021;57:27-35. [PMID: 33537216 DOI: 10.4068/cmj.2021.57.1.27] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
36 A Attia M, Enan ET, Hashish AA, M H El-Kannishy S, Gardouh AR, K Tawfik M, Faisal S, El-Mistekawy A, Salama A, Alomar SY, H Eltrawy A, Yagub Aloyouni S, Zaitone SA. Chemopreventive Effect of 5-Flurouracil Polymeric Hybrid PLGA-Lecithin Nanoparticles against Colon Dysplasia Model in Mice and Impact on p53 Apoptosis. Biomolecules 2021;11:109. [PMID: 33467560 DOI: 10.3390/biom11010109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]